Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review

Nasrin Abulhasanbeigi Gallehzan (), Majid Khosravi (), Khosro Jamebozorgi (), Nazanin Mir (), Habib Jalilian (), Samira Soleimanpour (), Saeed Hoseini (), Aziz Rezapour () and Abbas Eshraghi ()
Additional contact information
Nasrin Abulhasanbeigi Gallehzan: Health Management Research Institute, Iran University of Medical Sciences
Majid Khosravi: Health Management Research Institute, Iran University of Medical Sciences
Khosro Jamebozorgi: Zabol University of Medical Sciences
Nazanin Mir: Health Management Research Institute, Iran University of Medical Sciences
Habib Jalilian: Ahvaz Jundishapur University of Medical Sciences
Samira Soleimanpour: Iran University of Medical Sciences
Saeed Hoseini: Health Management Research Institute, Iran University of Medical Sciences
Aziz Rezapour: Iran University of Medical Sciences
Abbas Eshraghi: Tabriz University of Medical Sciences

Health Economics Review, 2024, vol. 14, issue 1, 1-37

Abstract: Abstract Background Multiple sclerosis (MS) is a chronic, autoimmune, and inflammatory disease. The economic burden of MS is substantial, and the high cost of Disease-modifying drugs (DMDs) prices are the main drivers of healthcare expenditures. We conducted a systematic review of studies evaluating the cost-utility and cost-effectiveness of DMDs for relapsing–remitting multiple sclerosis (RRMS). Materials and method Searches were conducted in PubMed, Web of Science, Scopus, and Embase. The search covered articles published between May 2001 and May 2023. Studies that were written in English and Persian and examined the cost-utility and cost-effectiveness of DMDs in patients with MS were included in our review. Data extraction was guided by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist, and the quality of economic evaluations was assessed using the Quality of Health Economics Studies Instrument (QHES). All costs were converted to 2020 U.S. dollars using Purchasing Power Parity (PPP). Results The search yielded 1589 studies, and 49 studies were eligible for inclusion. The studies were mainly based on a European setting. Most studies employed Markov model to assess the cost–effectiveness. The lowest and highest numerical value of outcome measures were -1,623,918 and 2,297,141.53, respectively. Furthermore, the lowest and highest numerical value of the cost of DMDs of RRMS were $180.67, and $1474840.19, respectively. Conclusions Based on the results of all studies, it can be concluded that for the treatment of patients with MS, care-oriented strategies should be preferred to drug strategies. Also, among the drug strategies with different prescribing methods, oral disease-modifying drugs of RRMS should be preferred to injectable drugs and intravenous infusions.

Keywords: Disease-modifying drugs; Relapsing–remitting multiple sclerosis; Cost-utility analysis; Cost-effectiveness analysis (search for similar items in EconPapers)
Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1186/s13561-024-00478-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:14:y:2024:i:1:d:10.1186_s13561-024-00478-7

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-024-00478-7

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().